The multikinase inhibitor sorafenib is, at present, the only drug approved for the treatment of
hepatocellular carcinoma (HCC), one of the most lethal types of cancer worldwide. However …

To systematically review the safety and efficacy of lenvatinib in the treatment of patients, we
retrieved all the relevant clinical trials on the adverse events (AEs) and survival outcomes of …

Medullary thyroid carcinoma (MTC) arises from parafollicular cells in the thyroid gland, and
although rare, it represents an aggressive type of thyroid cancer. MTC is recognized for its …

Since early seventies of the twentieth century, through seminal work of Judah Folkman,
angiogenesis, the process of new blood vessel sprouting from the existing vasculature, was …

Lenvatinib (Lenvima™) is a multitargeted receptor kinase inhibitor that inhibits the kinase
activities of vascular endothelial-derived growth factor receptors 1, 2 and 3, fibroblast growth …

BACKGROUND Thyroid cancer is a rare cancer, accounting for only 1% of all malignancies
in England and Wales. Differentiated thyroid cancer (DTC) accounts for≈ 94% of all thyroid …

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and the
fourth most frequent cause of cancer-related death worldwide. Sorafenib is the first line …

Thyroid cancer is one of the most common carcinomas of the endocrine system with an
increasing incidence. A growing number of studies have focused on the diagnostic and …

The most common thyroid malignancy is papillary thyroid cancer. While a majority respond
to therapy and have a favorable prognosis, some papillary thyroid cancers persist. This …

Papillary thyroid carcinoma (PTC) is the most common pathological type of thyroid cancer.
Our study was to construct a tissue-targeted metabolomics analysis method based on …